
    
      In response to developments in the treatment of melanoma, the sponsor reviewed the data from
      the ongoing study and decided to halt further enrollment of patients in the Phase Ib part of
      the study. Consequently, the Phase II part of the study was not performed. Early termination
      of the study was not due to any safety concerns.
    
  